Literature DB >> 30406943

Essential Characteristics of Pharmacogenomics Study Publications.

Caroline F Thorn1, Michelle Whirl-Carrillo1, Houda Hachad2, Julie A Johnson3, Ellen M McDonagh4, Mark J Ratain5, Mary V Relling6, Stuart A Scott7,8, Russ B Altman9,10, Teri E Klein1.   

Abstract

Pharmacogenomics (PGx) can be seen as a model for biomedical studies: it includes all disease areas of interest and spans in vitro studies to clinical trials, while focusing on the relationships between genes and drugs and the resulting phenotypes. This review will examine different characteristics of PGx study publications and provide examples of excellence in framing PGx questions and reporting their resulting data in a way that maximizes the knowledge that can be built on them.
© 2018 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Year:  2019        PMID： 30406943      PMCID： PMC6449845          DOI： 10.1002/cpt.1279

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  45 in total

1.  Pharmacogenetics: from bench to byte.

Authors:  J J Swen; I Wilting; A L de Goede; L Grandia; H Mulder; D J Touw; A de Boer; J M H Conemans; T C G Egberts; O H Klungel; R Koopmans; J van der Weide; B Wilffert; H-J Guchelaar; V H M Deneer
Journal:  Clin Pharmacol Ther       Date:  2008-02-06       Impact factor: 6.875

2.  Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).

Authors:  Caitrin W McDonough; Oyunbileg Magvanjav; Ana C C Sá; Nihal M El Rouby; Chintan Dave; Amelia N Deitchman; Marina Kawaguchi-Suzuki; Wenbin Mei; Yong Shen; Ravi Shankar Prasad Singh; Mohamed Solayman; Kent R Bailey; Eric Boerwinkle; Arlene B Chapman; John G Gums; Amy Webb; Steven E Scherer; Wolfgang Sadee; Stephen T Turner; Rhonda M Cooper-DeHoff; Yan Gong; Julie A Johnson
Journal:  Circ Genom Precis Med       Date:  2018-04

3.  Evidence based medicine: what it is and what it isn't.

Authors:  D L Sackett; W M Rosenberg; J A Gray; R B Haynes; W S Richardson
Journal:  BMJ       Date:  1996-01-13

4.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Lieh-Bang Liou; Chen-Chung Chu; Marie Lin; Hsien-Ping Huang; Yen-Ling Lin; Joung-Liang Lan; Li-Cheng Yang; Hong-Shang Hong; Ming-Jing Chen; Ping-Chin Lai; Mai-Szu Wu; Chia-Yu Chu; Kuo-Hsien Wang; Chien-Hsiun Chen; Cathy S J Fann; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

5.  CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.

Authors:  Stuart A Scott; Lisa Edelmann; Ruth Kornreich; Monica Erazo; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2007-07       Impact factor: 2.533

6.  Pharmacogene regulatory elements: from discovery to applications.

Authors:  Robin P Smith; Ernest T Lam; Svetlana Markova; Sook Wah Yee; Nadav Ahituv
Journal:  Genome Med       Date:  2012-05-25       Impact factor: 11.117

7.  The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database.

Authors:  Andrea Gaedigk; Magnus Ingelman-Sundberg; Neil A Miller; J Steven Leeder; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2017-11-14       Impact factor: 6.875

Review 8.  Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

Authors:  Femke M de Man; Andrew K L Goey; Ron H N van Schaik; Ron H J Mathijssen; Sander Bins
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

9.  CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Authors:  M A Province; M P Goetz; H Brauch; D A Flockhart; J M Hebert; R Whaley; V J Suman; W Schroth; S Winter; H Zembutsu; T Mushiroda; W G Newman; M-T M Lee; C B Ambrosone; M W Beckmann; J-Y Choi; A-S Dieudonné; P A Fasching; R Ferraldeschi; L Gong; E Haschke-Becher; A Howell; L B Jordan; U Hamann; K Kiyotani; P Krippl; D Lambrechts; A Latif; U Langsenlehner; W Lorizio; P Neven; A T Nguyen; B-W Park; C A Purdie; P Quinlan; W Renner; M Schmidt; M Schwab; J-G Shin; J C Stingl; P Wegman; S Wingren; A H B Wu; E Ziv; G Zirpoli; A M Thompson; V C Jordan; Y Nakamura; R B Altman; M M Ames; R M Weinshilboum; M Eichelbaum; J N Ingle; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2013-09-23       Impact factor: 6.875

10.  Investigation of the major cytochrome P450 1A2 genetic variant in a healthy Tibetan population in China.

Authors:  Yongchao Ren; Fang Liu; Xugang Shi; Tingting Geng; Dongya Yuan; Li Wang; Longli Kang; Tianbo Jin; Chao Chen
Journal:  Mol Med Rep       Date:  2017-05-29       Impact factor: 2.952
View more
  2 in total

1.  Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application.

Authors:  Brittany A Borden; Ellie H Jhun; Keith Danahey; Emily Schierer; Jeffrey L Apfelbaum; Magdalena Anitescu; Randall Knoebel; Sajid Shahul; Tien M Truong; Mark J Ratain; Peter H O'Donnell
Journal:  Pharmacogenomics J       Date:  2021-08-10       Impact factor: 3.245

Review 2.  UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation.

Authors:  Ryan S Nelson; Nathan D Seligson; Sal Bottiglieri; Estrella Carballido; Alex Del Cueto; Iman Imanirad; Richard Levine; Alexander S Parker; Sandra M Swain; Emma M Tillman; J Kevin Hicks
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.